Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Germany
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Mekinist (trametinib) is an oral targeted therapy that inhibits MEK1 and MEK2, key proteins in the MAPK signaling pathway that drives tumor growth in cancers with a BRAF V600 mutation. It is often used together with Tafinlar (dabrafenib) for enhanced effect.
Mekinist is FDA-approved, as monotherapy or in combination with dabrafenib, for adult patients with unresectable or metastatic melanoma carrying a BRAF V600 mutation. In combination with dabrafenib, it is also approved for adjuvant treatment of resected Stage III BRAF V600-mutant melanoma, for BRAF V600-mutant advanced non-small cell lung cancer, and for BRAF V600E-mutant anaplastic thyroid cancer.
By blocking MEK1/MEK2, trametinib interrupts the MAPK signaling cascade downstream of mutated BRAF, slowing or halting tumor cell growth.
The recommended dose is 2 mg orally once daily, taken at least 1 hour before or 2 hours after a meal, either alone or in combination with dabrafenib (150 mg twice daily), as determined by the treating oncologist.
Mekinist requires monitoring for several serious adverse effects, particularly when combined with dabrafenib.
Assess left ventricular ejection fraction before starting, at one month, and periodically during treatment.
Retinal vein occlusion and retinal pigment epithelial detachment have been reported. Perform ophthalmologic exams periodically and for any visual disturbances.
Monitor for new or worsening pulmonary symptoms; withhold or discontinue as needed.
Rash and other skin reactions can occur, including severe cases; monitor closely, especially in combination therapy.
Increased bleeding risk, particularly when combined with dabrafenib. Monitor for signs of bleeding.
Monitor blood glucose, particularly in diabetic patients.
Mekinist can cause fetal harm. Advise effective contraception during treatment and for a defined period after the final dose.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Mekinist (trametinib) is manufactured by Novartis and is frequently prescribed together with Tafinlar (dabrafenib) as a combination regimen for BRAF V600-mutant cancers.
Import of Mekinist through a Named Patient Program requires a valid prescription from the treating oncologist, confirmation of BRAF V600 mutation status via an FDA-approved test, and supporting clinical documentation as required by Indian regulatory authorities.
NPP sources Mekinist directly from Novartis's authorized supply chain to ensure product authenticity and regulatory compliance.
Mekinist is sourced through verified, GDP-compliant, cold-chain channels from Novartis's authorized supply chain to ensure authenticity and quality.
Mekinist tablets should be stored refrigerated at 2°C to 8°C, protected from moisture and light, and kept in the original carton.
Once sourced, Mekinist is packed and transported under continuous cold-chain conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.
Patients across India can access Mekinist through NPP's regulated import pathway, with oncology specialists in major cities supporting the treatment process.
Leading oncology centers in Mumbai support BRAF V600 mutation testing and treatment coordination for Mekinist access.
Delhi's major cancer hospitals assist patients with molecular testing and prescription support for Mekinist.
Bangalore's oncology network offers access to BRAF testing and treatment planning for eligible patients.
Chennai-based specialists coordinate Mekinist access alongside comprehensive melanoma and lung cancer care.
Hyderabad's cancer care institutions support patients pursuing Mekinist therapy following confirmed BRAF V600 mutation status.
Kolkata's oncology centers help coordinate documentation and treatment access for Mekinist.
Pune-based oncologists assist with BRAF mutation testing and Mekinist treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Mekinist.
Kochi's oncology units assist patients with the documentation needed for Mekinist access.
Chandigarh's cancer care centers support Mekinist treatment coordination for patients from North India.
Jaipur's oncology specialists help patients navigate the Mekinist access process.
Lucknow-based cancer centers assist patients pursuing Mekinist therapy.
Bhubaneswar's oncology institutions support access to Mekinist for eligible patients.
Guwahati's specialists help coordinate Mekinist access for patients across the Northeast.
Patients in other cities across India can also access Mekinist through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 09 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 09 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
